Greenleaf Trust Sells 932 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Greenleaf Trust reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 3.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,458 shares of the medical equipment provider's stock after selling 932 shares during the quarter. Greenleaf Trust's holdings in Intuitive Surgical were worth $13,104,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock worth $16,813,478,000 after buying an additional 360,591 shares during the period. Geode Capital Management LLC boosted its position in Intuitive Surgical by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock worth $4,039,200,000 after purchasing an additional 243,802 shares during the period. Norges Bank acquired a new stake in Intuitive Surgical in the 4th quarter valued at $2,401,493,000. Invesco Ltd. raised its position in Intuitive Surgical by 7.7% in the fourth quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock valued at $2,165,184,000 after purchasing an additional 295,025 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Intuitive Surgical by 15.8% during the fourth quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock worth $1,889,126,000 after purchasing an additional 494,496 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ISRG. Citigroup reaffirmed a "buy" rating and issued a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and reduced their price target for the company from $515.00 to $440.00 in a report on Monday, June 9th. Royal Bank Of Canada lowered their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Finally, Evercore ISI raised their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $592.59.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded up $0.83 on Wednesday, hitting $528.13. 1,380,875 shares of the company's stock traded hands, compared to its average volume of 1,670,939. The firm's 50-day moving average price is $537.77 and its two-hundred day moving average price is $536.93. The stock has a market capitalization of $189.29 billion, a PE ratio of 77.44, a price-to-earnings-growth ratio of 5.67 and a beta of 1.64. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same quarter last year, the business earned $1.50 earnings per share. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president owned 5,224 shares in the company, valued at $2,695,113.84. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,998 shares of company stock valued at $2,611,577 over the last ninety days. 0.70% of the stock is owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.